Compare CUBI & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CUBI | AAPG |
|---|---|---|
| Founded | 1994 | 2009 |
| Country | United States | China |
| Employees | 869 | 767 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | N/A | N/A |
| Metric | CUBI | AAPG |
|---|---|---|
| Price | $76.01 | $22.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $85.00 | $48.40 |
| AVG Volume (30 Days) | ★ 300.9K | 1.8K |
| Earning Date | 04-23-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.95 | $290.34 |
| Revenue Next Year | $9.50 | N/A |
| P/E Ratio | $11.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $49.76 | $20.11 |
| 52 Week High | $82.56 | $48.45 |
| Indicator | CUBI | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 55.09 | 39.08 |
| Support Level | $71.59 | $21.20 |
| Resistance Level | $79.23 | $25.23 |
| Average True Range (ATR) | 2.29 | 0.43 |
| MACD | -0.19 | -0.41 |
| Stochastic Oscillator | 52.88 | 1.30 |
Customers Bancorp Inc is a bank holding company conducting banking activities through its wholly owned subsidiary, Customers Bank. The Bank provides commercial and consumer customers the stability of a regulated financial institution supported by risk management. It serves commercial and corporate businesses nationwide, including healthcare, real estate, specialty finance, fund finance, technology and venture capital banking, mortgage finance and commercial equipment financing, and provides payments and treasury services. The Bank also serves consumers through its branch network, offering residential mortgages and personal loan and deposit products, including Banking-as-a-Service, with services delivered predominantly in Southeastern and Central Pennsylvania, New York, and other states.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.